As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: April 24, 2014
by Health Canal:
Since the time of Dr. Alois Alzheimer himself, two proteins (beta-amyloid (Aβ) and tau) have become tantamount to Alzheimer’s disease (AD). But a Mayo Clinic study challenges the perception that these are the only important proteins accounting for the clinical features of the devastating disease.
A Third Protein Provides Clue
In a large clinico-imaging pathological study, Mayo Clinic researchers demonstrated that a third protein (TDP-43) plays a major role in AD pathology. In fact, people whose brain was TDP positive were 10 times more likely to be cognitively impaired at death compared to those who didn’t have the protein, showing that TDP-43 has the potential to overpower what has been termed resilient brain aging.
The study was published in the journal Acta Neuropathologica.
Mayo Clinic researchers studied brains of 342 patients who had died with pathologically confirmed AD and divided them into two groups based on the presence or absence of the protein TDP-43. The protein was found in 195 or 57 percent of the cases.
“We wanted to determine whether the TDP-43 protein has any independent effect on the clinical and neuroimaging features typically ascribed to AD and we found that TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD,” says Mayo Clinic neurologist Keith Josephs, M.D., the study’s lead investigator and author. “
In the early stages of the disease when AD pathology was less severe, the presence of TDP-43 was strongly associated with cognitive impairment. Consequently, TDP-43 appears to play an important role in the cognitive and neuroimaging characteristics that have been linked to AD.”
The study also found that patients who suffered from greater cognitive impairment and medial temporal atrophy at the time of death had greater TDP-43 burden and had the protein in a greater number of brain regions.
“This is why we believe that TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD and explain why some patients remain clinically normal, while others do not, despite both having similar degrees of AD pathology,” says Dr. Josephs. “Our findings suggest that in order to have AD and be cognitively resilient, TDP-43 must be absent, so it should be considered a potential therapeutic target for the future treatment of AD.
It is a devastating omission that may have undercut years of work by brilliant researchers from around the world. Millions of dollars and countless hours have been spent investigating dementia. But in the view of...
A stroll through the Dutch community of De Hogeweyk is a journey to what could be the future of dementia care. Located within the small town of Weesp, just outside of Amsterdam, De Hogeweyk is...
Intimate-partner violence (IPV) is a pattern of physical and/or sexual violence inflicted by an intimate or ex-intimate partner. Global estimates published by the World Health Organization indicate that about 1 in 3 women have experienced...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.